• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

作者信息

Ludwig H, Weisel K, Petrucci M T, Leleu X, Cafro A M, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M

机构信息

Wilhelminen Cancer Research Institute, Wilhelminenspital Wien, Wien, Austria.

Internal Medicine II, University of Tübingen, Tübingen, Germany.

出版信息

Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11.

DOI:10.1038/leu.2017.5
PMID:28074071
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5383929/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6b/5383929/44c014b1b838/leu20175f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6b/5383929/44c014b1b838/leu20175f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f6b/5383929/44c014b1b838/leu20175f1.jpg

相似文献

1
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.奥拉培塞德聚乙二醇，一种抗CXCL12/SDF-1 Spiegelmer，单药及与硼替佐米-地塞米松联合用于复发/难治性多发性骨髓瘤：一项IIa期研究。
Leukemia. 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11.
2
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.一项II期试验，旨在研究苯达莫司汀、地塞米松和沙利度胺在接受来那度胺和硼替佐米治疗后的复发或难治性多发性骨髓瘤患者中的疗效和安全性。
Br J Haematol. 2019 Jun;185(5):944-947. doi: 10.1111/bjh.15645. Epub 2018 Nov 26.
3
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.塞利尼索、硼替佐米与地塞米松（SVD方案）用于多次治疗后的复发难治性多发性骨髓瘤
Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.
4
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.奈非那韦-硼替佐米-地塞米松在蛋白酶体抑制剂难治性多发性骨髓瘤中显示出有前景的活性。
Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.
5
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.来那度胺联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者的多中心 I/II 期临床试验结果。
J Clin Oncol. 2011 Nov 10;29(32):4243-9. doi: 10.1200/JCO.2010.33.9788. Epub 2011 Oct 11.
6
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.硼替佐米、沙利度胺、地塞米松和帕比司他用于复发多发性骨髓瘤患者（MUK-six）：一项多中心、开放标签的1/2期试验
Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.
7
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.帕比司他与硼替佐米及地塞米松联合应用于复发和复发/难治性多发性骨髓瘤患者的药代动力学/药效学特征
Eur J Clin Pharmacol. 2016 Feb;72(2):153-61. doi: 10.1007/s00228-015-1967-z. Epub 2015 Oct 22.
8
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.硼替佐米联合来那度胺及地塞米松每周给药方案用于首次复发或原发性难治性骨髓瘤的I/II期试验
Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.
9
Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.一名复发多发性骨髓瘤患者的副肿瘤性主动脉炎经达雷妥尤单抗、硼替佐米和地塞米松成功治疗。
Ann Hematol. 2021 Jun;100(6):1623-1624. doi: 10.1007/s00277-020-04369-9. Epub 2021 Jan 6.
10
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.泊马度胺与低剂量地塞米松可改善复发/难治性多发性骨髓瘤患者的健康相关生活质量，并延长MM-003随机III期试验中患者病情恶化的时间。
Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):519-30. doi: 10.1016/j.clml.2015.05.007. Epub 2015 Jun 6.

引用本文的文献

1
Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.骨科疾病中的核酸适配体：治疗骨病的潜在治疗剂。
Bone Res. 2025 Jul 24;13(1):71. doi: 10.1038/s41413-025-00447-8.
2
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.小核酸疗法全景：作为下一代药物从实验室走向临床
Signal Transduct Target Ther. 2025 Mar 10;10(1):73. doi: 10.1038/s41392-024-02112-8.
3
Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.

本文引用的文献

1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
2
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.卡非佐米和地塞米松与硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的比较（ENDEAVOR）：一项随机、3 期、开放标签、多中心研究。
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
3
Targeting SDF-1 in multiple myeloma tumor microenvironment.
膀胱癌中的肿瘤相关巨噬细胞：作用和靶向治疗策略。
Front Immunol. 2024 Nov 13;15:1418131. doi: 10.3389/fimmu.2024.1418131. eCollection 2024.
4
The clinical potential of l-oligonucleotides: challenges and opportunities.L-寡核苷酸的临床潜力：挑战与机遇。
Chem Sci. 2024 Oct 21;15(44):18239-58. doi: 10.1039/d4sc05157b.
5
Therapeutic Applications of Aptamers.适体的治疗应用。
Int J Mol Sci. 2024 Jun 19;25(12):6742. doi: 10.3390/ijms25126742.
6
Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM).多发性骨髓瘤（MM）的趋化因子/趋化因子受体轴在肿瘤生物学中的研究进展。
Cell Commun Signal. 2024 Mar 12;22(1):177. doi: 10.1186/s12964-024-01544-7.
7
Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.多发性骨髓瘤肿瘤微环境中耐药性背后的代谢变化。
Front Oncol. 2023 Apr 6;13:1155621. doi: 10.3389/fonc.2023.1155621. eCollection 2023.
8
CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.CXC 趋化因子受体 4（CXCR4）在癌症治疗中的阻断作用。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7945-7968. doi: 10.1007/s00432-022-04444-w. Epub 2023 Mar 11.
9
The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.趋化因子 CXCL8 和 CXCL12：分子和功能特性、在疾病中的作用以及药理学干预的努力。
Cell Mol Immunol. 2023 Mar;20(3):217-251. doi: 10.1038/s41423-023-00974-6. Epub 2023 Feb 1.
10
The prospect of tumor microenvironment-modulating therapeutical strategies.肿瘤微环境调节治疗策略的前景。
Front Oncol. 2022 Dec 8;12:1070243. doi: 10.3389/fonc.2022.1070243. eCollection 2022.
靶向多发性骨髓瘤肿瘤微环境中的基质细胞衍生因子-1
Cancer Lett. 2016 Sep 28;380(1):315-8. doi: 10.1016/j.canlet.2015.11.028. Epub 2015 Nov 30.
4
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.硼替佐米联合地塞米松治疗复发性多发性骨髓瘤可改善预后，但持续维持治疗获益甚微。
Am J Hematol. 2015 May;90(5):E86-91. doi: 10.1002/ajh.23967. Epub 2015 Feb 27.
5
SDF-1 inhibition targets the bone marrow niche for cancer therapy.抑制基质细胞衍生因子-1可靶向作用于骨髓生态位以进行癌症治疗。
Cell Rep. 2014 Oct 9;9(1):118-128. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25.
6
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.帕比司他联合硼替佐米和地塞米松对比硼替佐米和地塞米松联合安慰剂治疗复发或复发难治性多发性骨髓瘤患者：一项多中心、随机、双盲的 3 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
7
CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.CXCR7 依赖性血管生成单核细胞迁移调节多发性骨髓瘤中的肿瘤进展。
Blood. 2014 Sep 18;124(12):1905-14. doi: 10.1182/blood-2014-02-558742.
8
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.苯达莫司汀-硼替佐米-地塞米松是一种在复发或难治性多发性骨髓瘤患者中具有活性且耐受性良好的方案。
Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.
9
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.硼替佐米-地塞米松单药或联合环磷酰胺或来那度胺治疗二线治疗多发性骨髓瘤患者亚最佳反应的 II 期研究。
Haematologica. 2013 Aug;98(8):1264-72. doi: 10.3324/haematol.2013.084376. Epub 2013 May 28.
10
Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.一种新型 CXCL12 单链寡核苷酸抑制剂在小鼠和人体内对造血干/祖细胞的动员作用。
Clin Pharmacol Ther. 2013 Jul;94(1):150-7. doi: 10.1038/clpt.2013.58. Epub 2013 Mar 19.